Literature DB >> 19513748

Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.

Fuqin Su1, Hongyan Li, Chaoqi Yan, Baoqing Jia, Yi Zhang, Xiaoguang Chen.   

Abstract

BACKGROUND: Mitogen-activated protein/ERK kinase 1 (MEKK1) is a Ser/Thr protein kinase belonging to the MEKK/STE11 subgroup of the MAPKKK family and plays a key role in tumor metastasis. However, it remains unclear about its functions in pancreatic cancer.
MATERIALS AND METHODS: We analyzed MEKK1 expression in 41 surgically resection pancreatic cancer patient's samples by immunohistochemistry and determined its role in BxPC3 cells via RNAi experiment. The abilities of invasion, motility, and adhesion of BxPC3 cells were detected by transwell assay, wound healing assay and adhesion assay, respectively. Gelatinase activity of MMPs in cultured cells was examined by gelatin zymography.
RESULTS: Our data showed that MEKK1 expression is positively correlated with lymphatic metastases (P < 0.01). The abilities of invasion, motility, and adhesion of BxPC3 cells were inhibited significantly (P < 0.01) when MEKK1 was depleted with a specific siRNA. We observed that the activity of MMP2 was decreased in the MEKK1 depletion cell line (P < 0.05), accompanied with decreased phosphorylated ERK1/2.
CONCLUSION: Our results indicated that the depletion of MEKK1 led to a potent inhibition on the invasion and migration of human pancreatic adenocarcinoma in vitro. It suggests that MEKK1 may be a potential target for development of anti-invasion and metastasis drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513748     DOI: 10.1007/s00432-009-0612-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  19 in total

1.  High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.

Authors:  Y Seo; H Baba; T Fukuda; M Takashima; K Sugimachi
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

2.  Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique.

Authors:  Mark Bloomston; Atul Bhardwaj; E Christopher Ellison; Wendy L Frankel
Journal:  Dig Surg       Date:  2006-05-23       Impact factor: 2.588

3.  Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors.

Authors:  Hiroyuki Yamasaki; Satoshi Ikeda; Masazumi Okajima; Yoshio Miura; Toshimasa Asahara; Nobuoki Kohno; Fumio Shimamoto
Journal:  Int J Oncol       Date:  2004-01       Impact factor: 5.650

4.  Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.

Authors:  Dafang Bian; Shibing Su; Chitladda Mahanivong; Robert K Cheng; Qiwei Han; Zhixing K Pan; Peiqing Sun; Shuang Huang
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

Review 5.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

Authors:  R H Hruban; A D van Mansfeld; G J Offerhaus; D H van Weering; D C Allison; S N Goodman; T W Kensler; K K Bose; J L Cameron; J L Bos
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt.

Authors:  Helena Doucas; Christopher D Mann; Christopher D Sutton; Guiseppe Garcea; Christopher P Neal; David P Berry; Margaret M Manson
Journal:  J Surg Oncol       Date:  2008-01-01       Impact factor: 3.454

7.  Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma.

Authors:  Li Zhou; Xiao-Dong He; Quan-Cai Cui; Wei-Xun Zhou; Qiang Qu; Rou-Li Zhou; Jing-An Rui; Jian-Chun Yu
Journal:  Cancer Lett       Date:  2008-03-10       Impact factor: 8.679

8.  The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.

Authors:  Takayuki Asano; Yixin Yao; Jijiang Zhu; Donghui Li; James L Abbruzzese; Shrikanth A G Reddy
Journal:  Oncogene       Date:  2004-11-11       Impact factor: 9.867

Review 9.  Development and controversies of adjuvant therapy for pancreatic cancer.

Authors:  Wan-Yee Lau; Eric C H Lai
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-04

10.  Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma.

Authors:  Ardeshir Hakam; Quan Fang; Richard Karl; Domenico Coppola
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

View more
  13 in total

1.  MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis.

Authors:  Trang T Pham; Steven P Angus; Gary L Johnson
Journal:  Genes Cancer       Date:  2013-11

2.  Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.

Authors:  Laura Conradt; Klaus Godl; Christoph Schaab; Andreas Tebbe; Stefan Eser; Sandra Diersch; Christoph W Michalski; Jörg Kleeff; Angelika Schnieke; Roland M Schmid; Dieter Saur; Günter Schneider
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

3.  Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.

Authors:  Venkata Ramesh Dasari; Kiranpreet Kaur; Kiran Kumar Velpula; Meena Gujrati; Daniel Fassett; Jeffrey D Klopfenstein; Dzung H Dinh; Jasti S Rao
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

4.  Functional interaction between Env oncogene from Jaagsiekte sheep retrovirus and tumor suppressor Sprouty2.

Authors:  Ebenezer Chitra; Yi-Wen Lin; Fabian Davamani; Kuang-Nan Hsiao; Charles Sia; Shih-Yang Hsieh; Olivia L Wei; Jen-Hao Chen; Yen-Hung Chow
Journal:  Retrovirology       Date:  2010-08-02       Impact factor: 4.602

5.  Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer.

Authors:  Ying Chen; Qingqu Guo; Bo Zhang; Muxing Kang; Qiuping Xie; Yulian Wu
Journal:  Oncol Lett       Date:  2012-07-02       Impact factor: 2.967

6.  Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion.

Authors:  Cameron P Bracken; Xiaochun Li; Josephine A Wright; David M Lawrence; Katherine A Pillman; Marika Salmanidis; Matthew A Anderson; B Kate Dredge; Philip A Gregory; Anna Tsykin; Corine Neilsen; Daniel W Thomson; Andrew G Bert; Joanne M Leerberg; Alpha S Yap; Kirk B Jensen; Yeesim Khew-Goodall; Gregory J Goodall
Journal:  EMBO J       Date:  2014-07-28       Impact factor: 11.598

7.  Small interfering RNA-mediated downregulation of beta-catenin inhibits invasion and migration of colon cancer cells in vitro.

Authors:  Jianjun Han; Binbin Gao; Xing Jin; Zhongfa Xu; Zengjun Li; Yanlai Sun; Bao Song
Journal:  Med Sci Monit       Date:  2012-07

8.  MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro.

Authors:  Chun Liu; Shengjie Wang; Shunxing Zhu; Haifeng Wang; Jiayi Gu; Zeping Gui; Jin Jing; Xiaofan Hou; Yixiang Shao
Journal:  Springerplus       Date:  2016-01-04

9.  Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells.

Authors:  Bo Huang; Hongli Zhou; Xiaodong Wang; Zhiliang Liu
Journal:  Cancer Cell Int       Date:  2013-02-05       Impact factor: 5.722

10.  RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA.

Authors:  Meng Zhang; Senlin Zhao; Cong Tan; Yanzi Gu; Xuefeng He; Xiang Du; Dawei Li; Ping Wei
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.